{"id": "article-511_0", "title": "Poly-L-Lactic Acid -- Continuing Education Activity", "content": "Poly-L-lactic acid is an injectable implant renowned for its absorbable and semi-permanent nature, exhibiting the unique capability to restore volume and prompt collagen formation gradually. With FDA approval specifically for addressing facial fat loss linked to antiretroviral therapy-induced lipoatrophy in HIV patients, this implant is effective for correcting nasolabial fold deficiencies and various facial wrinkles in immunocompetent individuals. Beyond its approved applications, poly-L-lactic acid is used off-label in augmenting areas such as cheeks, hands, neck, thighs, gluteal enhancement, and rectifying chest wall deformities like pectus excavatum or thoracic deformities post-surgical procedures.", "contents": "Poly-L-Lactic Acid -- Continuing Education Activity. Poly-L-lactic acid is an injectable implant renowned for its absorbable and semi-permanent nature, exhibiting the unique capability to restore volume and prompt collagen formation gradually. With FDA approval specifically for addressing facial fat loss linked to antiretroviral therapy-induced lipoatrophy in HIV patients, this implant is effective for correcting nasolabial fold deficiencies and various facial wrinkles in immunocompetent individuals. Beyond its approved applications, poly-L-lactic acid is used off-label in augmenting areas such as cheeks, hands, neck, thighs, gluteal enhancement, and rectifying chest wall deformities like pectus excavatum or thoracic deformities post-surgical procedures."}
{"id": "article-511_1", "title": "Poly-L-Lactic Acid -- Continuing Education Activity", "content": "This activity discusses poly-L-lactic acid's mode of action, modes of administration, potential adverse events, eligible patient populations, and monitoring protocols. Emphasizing the pivotal role of the interprofessional team in managing patients undergoing poly-L-lactic acid treatment, this educational initiative provides a thorough understanding of this cutting-edge intervention, fostering enhanced patient care and outcomes.", "contents": "Poly-L-Lactic Acid -- Continuing Education Activity. This activity discusses poly-L-lactic acid's mode of action, modes of administration, potential adverse events, eligible patient populations, and monitoring protocols. Emphasizing the pivotal role of the interprofessional team in managing patients undergoing poly-L-lactic acid treatment, this educational initiative provides a thorough understanding of this cutting-edge intervention, fostering enhanced patient care and outcomes."}
{"id": "article-511_2", "title": "Poly-L-Lactic Acid -- Continuing Education Activity", "content": "Objectives: Identify appropriate candidates for poly-L-lactic acid injections based on patient-specific factors, such as age, skin condition, and desired aesthetic outcomes. Screen patients for contraindications, potential allergies, and medical history that may impact poly-L-lactic acid's safe and effective use. Develop\u00a0effective communication with patients, providing detailed information about poly-L-lactic acid, its expected outcomes, potential side effects, and the importance of realistic expectations. Implement strategies\u00a0with dermatologists, plastic surgeons, and other healthcare professionals to ensure comprehensive care and an interdisciplinary approach to patients undergoing poly-L-lactic acid treatments. Access free multiple choice questions on this topic.", "contents": "Poly-L-Lactic Acid -- Continuing Education Activity. Objectives: Identify appropriate candidates for poly-L-lactic acid injections based on patient-specific factors, such as age, skin condition, and desired aesthetic outcomes. Screen patients for contraindications, potential allergies, and medical history that may impact poly-L-lactic acid's safe and effective use. Develop\u00a0effective communication with patients, providing detailed information about poly-L-lactic acid, its expected outcomes, potential side effects, and the importance of realistic expectations. Implement strategies\u00a0with dermatologists, plastic surgeons, and other healthcare professionals to ensure comprehensive care and an interdisciplinary approach to patients undergoing poly-L-lactic acid treatments. Access free multiple choice questions on this topic."}
{"id": "article-511_3", "title": "Poly-L-Lactic Acid -- Indications -- FDA-Approved Indications", "content": "Poly-L-lactic acid (PLLA) is an absorbable, semi-permanent, injectable implant that can restore volume and gradually stimulate collagen formation.\u00a0Poly-L-lactic\u00a0acid is FDA-approved for correcting facial fat loss associated with antiretroviral therapy-induced lipoatrophy in HIV patients. PLLA is FDA-approved for immunocompetent people to correct nasolabial fold deficiencies and other facial wrinkles.", "contents": "Poly-L-Lactic Acid -- Indications -- FDA-Approved Indications. Poly-L-lactic acid (PLLA) is an absorbable, semi-permanent, injectable implant that can restore volume and gradually stimulate collagen formation.\u00a0Poly-L-lactic\u00a0acid is FDA-approved for correcting facial fat loss associated with antiretroviral therapy-induced lipoatrophy in HIV patients. PLLA is FDA-approved for immunocompetent people to correct nasolabial fold deficiencies and other facial wrinkles."}
{"id": "article-511_4", "title": "Poly-L-Lactic Acid -- Indications -- Off-Label Uses", "content": "PLLA has been used off-label to enhance the cheeks, hands, neck, and thighs, gluteal enhancement, and chest wall deformities, such as pectus excavatum or thoracic deformities secondary to surgical procedures. [1] [2] Poly-L-lactic acid has been reported to improve \"step-off\" chest wall deformities after mastectomy and implant reconstruction, suggesting that this product can also help improve breast abnormalities. For maximal correction, a series of injections is recommended at 3 to 6-week intervals. The degree of lipoatrophy correction is based on the number of sessions, not the volume injected at each session. [3] PLLA is also used for non-facial body treatments to address skin laxity, reduce cellulite, and treat scars. [4]", "contents": "Poly-L-Lactic Acid -- Indications -- Off-Label Uses. PLLA has been used off-label to enhance the cheeks, hands, neck, and thighs, gluteal enhancement, and chest wall deformities, such as pectus excavatum or thoracic deformities secondary to surgical procedures. [1] [2] Poly-L-lactic acid has been reported to improve \"step-off\" chest wall deformities after mastectomy and implant reconstruction, suggesting that this product can also help improve breast abnormalities. For maximal correction, a series of injections is recommended at 3 to 6-week intervals. The degree of lipoatrophy correction is based on the number of sessions, not the volume injected at each session. [3] PLLA is also used for non-facial body treatments to address skin laxity, reduce cellulite, and treat scars. [4]"}
{"id": "article-511_5", "title": "Poly-L-Lactic Acid -- Indications -- Off-Label Uses", "content": "Recent\u00a0research suggested the role of PLLA in meningomyelocele (MMC). Poly-L-lactic\u00a0acid (PLLA) played a crucial role in the novel patch design for MMC repair conducted by researchers. By blending PLLA with poly (\u03b5-caprolactone), the researchers aimed to address the limitations of existing patch materials. The importance of PLLA was underscored by its favorable degradation behavior and ability to maintain structural integrity throughout the 16-week study period. This emphasized PLLA's potential as a critical component in creating a superior alternative for meningomyelocele repair, offering promising possibilities for improved patient outcomes. Additional animal and human studies are required. [5]", "contents": "Poly-L-Lactic Acid -- Indications -- Off-Label Uses. Recent\u00a0research suggested the role of PLLA in meningomyelocele (MMC). Poly-L-lactic\u00a0acid (PLLA) played a crucial role in the novel patch design for MMC repair conducted by researchers. By blending PLLA with poly (\u03b5-caprolactone), the researchers aimed to address the limitations of existing patch materials. The importance of PLLA was underscored by its favorable degradation behavior and ability to maintain structural integrity throughout the 16-week study period. This emphasized PLLA's potential as a critical component in creating a superior alternative for meningomyelocele repair, offering promising possibilities for improved patient outcomes. Additional animal and human studies are required. [5]"}
{"id": "article-511_6", "title": "Poly-L-Lactic Acid -- Mechanism of Action", "content": "Injection of poly-L-lactic acid into the deep dermis or subcutaneous tissue may immediately augment the treated tissue. This is a temporary but\u00a0immediate response due to tissue edema and fluid from the reconstitution of the product. This usually resolves within 2 to 3 days after injection.", "contents": "Poly-L-Lactic Acid -- Mechanism of Action. Injection of poly-L-lactic acid into the deep dermis or subcutaneous tissue may immediately augment the treated tissue. This is a temporary but\u00a0immediate response due to tissue edema and fluid from the reconstitution of the product. This usually resolves within 2 to 3 days after injection."}
{"id": "article-511_7", "title": "Poly-L-Lactic Acid -- Mechanism of Action", "content": "Once the carrier substance is absorbed, the poly-L-lactic acid particles induce an inflammatory response through phagocytosis by tissue macrophages. This is a similar process to suture reabsorption in the skin. The inflammatory response breaks down the poly-L-lactic acid into lactic acid monomers.\u00a0These are\u00a0then metabolized to carbon dioxide and water while stimulating the production of new collagen type-I fibers in the skin. Approximately half of the product is digested within\u00a06 months. The duration of action is 12 to 24 months. [6] [7] [8] Neutrophils, macrophages, and fibroblasts play a role in enzymatic degradation. These cells secrete acid phosphatase and lactate dehydrogenase, which actively enhance the degradation of PLLA. [9]", "contents": "Poly-L-Lactic Acid -- Mechanism of Action. Once the carrier substance is absorbed, the poly-L-lactic acid particles induce an inflammatory response through phagocytosis by tissue macrophages. This is a similar process to suture reabsorption in the skin. The inflammatory response breaks down the poly-L-lactic acid into lactic acid monomers.\u00a0These are\u00a0then metabolized to carbon dioxide and water while stimulating the production of new collagen type-I fibers in the skin. Approximately half of the product is digested within\u00a06 months. The duration of action is 12 to 24 months. [6] [7] [8] Neutrophils, macrophages, and fibroblasts play a role in enzymatic degradation. These cells secrete acid phosphatase and lactate dehydrogenase, which actively enhance the degradation of PLLA. [9]"}
{"id": "article-511_8", "title": "Poly-L-Lactic Acid -- Administration -- Available Dosage Forms and Strengths", "content": "Poly-L-lactic acid is available as microparticles of lyophilized, alpha-hydroxy acid polymers similar in structure to the polyglactin 910 suture material manufactured\u00a0in powder form. Poly-L-lactic acid comes in a carton containing\u00a02 vials. Each vial contains 367.5 g of product and is reconstituted with 4 mL of sterile water and 1 mL of lidocaine, producing a 5 mL suspension of 4.45% poly-L-lactic acid. Higher dilution volumes can be used.", "contents": "Poly-L-Lactic Acid -- Administration -- Available Dosage Forms and Strengths. Poly-L-lactic acid is available as microparticles of lyophilized, alpha-hydroxy acid polymers similar in structure to the polyglactin 910 suture material manufactured\u00a0in powder form. Poly-L-lactic acid comes in a carton containing\u00a02 vials. Each vial contains 367.5 g of product and is reconstituted with 4 mL of sterile water and 1 mL of lidocaine, producing a 5 mL suspension of 4.45% poly-L-lactic acid. Higher dilution volumes can be used."}
{"id": "article-511_9", "title": "Poly-L-Lactic Acid -- Administration -- Available Dosage Forms and Strengths", "content": "Once diluted, it should be allowed to stand undisturbed for 2 to 4 hours and swirled immediately before injection to ensure an even suspension of particles. Some injectors recommend dilution 24 to 72 hours before injection to allow appropriate powder saturation. [10] [11] The vials are intended for single-patient use only\u00a0and should not\u00a0be reused or resterilized. If the package or vial is opened or damaged, it should not be used.", "contents": "Poly-L-Lactic Acid -- Administration -- Available Dosage Forms and Strengths. Once diluted, it should be allowed to stand undisturbed for 2 to 4 hours and swirled immediately before injection to ensure an even suspension of particles. Some injectors recommend dilution 24 to 72 hours before injection to allow appropriate powder saturation. [10] [11] The vials are intended for single-patient use only\u00a0and should not\u00a0be reused or resterilized. If the package or vial is opened or damaged, it should not be used."}
{"id": "article-511_10", "title": "Poly-L-Lactic Acid -- Administration -- Available Dosage Forms and Strengths", "content": "The product does not require refrigeration once reconstituted. The poly-L-lactic acid is placed into the deep dermis or subcutaneous tissue using a 26-gauge needle, roughly\u00a01 vial per side of the face. Various injection techniques, including linear threading, depot injection in small volumes, and cross-hatching, can be used. Massage should be performed during and after the injection to ensure an even distribution of the material. The patient should apply ice packs to the treatment areas to reduce erythema and swelling. [12] [13]", "contents": "Poly-L-Lactic Acid -- Administration -- Available Dosage Forms and Strengths. The product does not require refrigeration once reconstituted. The poly-L-lactic acid is placed into the deep dermis or subcutaneous tissue using a 26-gauge needle, roughly\u00a01 vial per side of the face. Various injection techniques, including linear threading, depot injection in small volumes, and cross-hatching, can be used. Massage should be performed during and after the injection to ensure an even distribution of the material. The patient should apply ice packs to the treatment areas to reduce erythema and swelling. [12] [13]"}
{"id": "article-511_11", "title": "Poly-L-Lactic Acid -- Administration -- Available Dosage Forms and Strengths", "content": "Overcorrecting the nasolabial fold contour defect by overfilling should be avoided, as the depression is expected to gradually improve over several weeks following the injection when the effects of PLLA become evident. [14] The cross-fanning injection technique has been employed in research studies involving patients with HIV-related facial lipoatrophy and immune-competent patients undergoing treatment for aging-related facial lipoatrophy. Pregnancy considerations: The safety and efficacy of poly-L-lactic acid (PLLA) have not been systematically evaluated in pregnant patients. [15] Breastfeeding considerations: PLLA has not been evaluated in lactation. [16] Pediatric patients: The safety and efficacy of poly-L-lactic acid have not been established in individuals\u00a0younger than 18.", "contents": "Poly-L-Lactic Acid -- Administration -- Available Dosage Forms and Strengths. Overcorrecting the nasolabial fold contour defect by overfilling should be avoided, as the depression is expected to gradually improve over several weeks following the injection when the effects of PLLA become evident. [14] The cross-fanning injection technique has been employed in research studies involving patients with HIV-related facial lipoatrophy and immune-competent patients undergoing treatment for aging-related facial lipoatrophy. Pregnancy considerations: The safety and efficacy of poly-L-lactic acid (PLLA) have not been systematically evaluated in pregnant patients. [15] Breastfeeding considerations: PLLA has not been evaluated in lactation. [16] Pediatric patients: The safety and efficacy of poly-L-lactic acid have not been established in individuals\u00a0younger than 18."}
{"id": "article-511_12", "title": "Poly-L-Lactic Acid -- Administration -- Available Dosage Forms and Strengths", "content": "Older patients :\u00a0Collagen production diminishes with age and sun exposure, leading to visible wrinkles. PLLA, a dermal filler, is injected into the deep skin layer to stimulate collagen production. PLLA particles initially fill the wrinkles and gradually degrade, stimulating the body's production of new collagen.", "contents": "Poly-L-Lactic Acid -- Administration -- Available Dosage Forms and Strengths. Older patients :\u00a0Collagen production diminishes with age and sun exposure, leading to visible wrinkles. PLLA, a dermal filler, is injected into the deep skin layer to stimulate collagen production. PLLA particles initially fill the wrinkles and gradually degrade, stimulating the body's production of new collagen."}
{"id": "article-511_13", "title": "Poly-L-Lactic Acid -- Adverse Effects", "content": "Acute injection site reaction is the most common adverse effect of administering this product. This can manifest as erythema, swelling, or bruising that can take up to a\u00a0week to heal.\u00a0Optimal administration of poly-L-lactic\u00a0acid (PLLA)\u00a0involves\u00a0deep dermal injection to minimize the incidence of adverse events.\u00a0The aseptic technique must be strictly adhered to during poly-L-lactic\u00a0acid sessions to reduce the risk of infection.\u00a0Immediate application of ice compression following the injection is recommended while decreasing direct exposure to sunlight. [17]", "contents": "Poly-L-Lactic Acid -- Adverse Effects. Acute injection site reaction is the most common adverse effect of administering this product. This can manifest as erythema, swelling, or bruising that can take up to a\u00a0week to heal.\u00a0Optimal administration of poly-L-lactic\u00a0acid (PLLA)\u00a0involves\u00a0deep dermal injection to minimize the incidence of adverse events.\u00a0The aseptic technique must be strictly adhered to during poly-L-lactic\u00a0acid sessions to reduce the risk of infection.\u00a0Immediate application of ice compression following the injection is recommended while decreasing direct exposure to sunlight. [17]"}
{"id": "article-511_14", "title": "Poly-L-Lactic Acid -- Adverse Effects", "content": "Poly-L-lactic acid is a foreign substance. Therefore, it risks a hypersensitivity reaction upon injection into the skin. Patients should remove all makeup, and the skin should be adequately prepped before injection to minimize the introduction of additional foreign particles. Skin testing can be performed before treatment.", "contents": "Poly-L-Lactic Acid -- Adverse Effects. Poly-L-lactic acid is a foreign substance. Therefore, it risks a hypersensitivity reaction upon injection into the skin. Patients should remove all makeup, and the skin should be adequately prepped before injection to minimize the introduction of additional foreign particles. Skin testing can be performed before treatment."}
{"id": "article-511_15", "title": "Poly-L-Lactic Acid -- Adverse Effects", "content": "Post-treatment nodules with granuloma formation can occur with an injection of this product. [18] The risk is thought to be due to lower dilution volumes, and studies have shown that a decreased risk exists when dilution of volumes of 7 mL or more is used. A post-injection massage is recommended to be performed for 5 minutes at a time,\u00a05 times a day for\u00a05 days after injection, and has been anecdotally recommended to help minimize the occurrence of nodules. Injectors can also place smaller aliquots of the product deeper in the skin to help reduce this risk.", "contents": "Poly-L-Lactic Acid -- Adverse Effects. Post-treatment nodules with granuloma formation can occur with an injection of this product. [18] The risk is thought to be due to lower dilution volumes, and studies have shown that a decreased risk exists when dilution of volumes of 7 mL or more is used. A post-injection massage is recommended to be performed for 5 minutes at a time,\u00a05 times a day for\u00a05 days after injection, and has been anecdotally recommended to help minimize the occurrence of nodules. Injectors can also place smaller aliquots of the product deeper in the skin to help reduce this risk."}
{"id": "article-511_16", "title": "Poly-L-Lactic Acid -- Adverse Effects", "content": "Several treatments\u00a0are available if the patient experiences nodule formation. Early-onset lesions can be treated with subcision or injected with sterile water. Later-onset nodules can be treated with intralesional triamcinolone up to 40 mg/mL or 5-fluorouracil 2% or 5% combined with a low-dose oral tetracycline antibiotic. There are some reports that oral prednisone may be used to help suppress the formation of nodules. Inappropriate placement of this product in the skin can lead to lumpiness or visibility of the filler through the skin. Post-treatment massage to the area can help decrease this risk.", "contents": "Poly-L-Lactic Acid -- Adverse Effects. Several treatments\u00a0are available if the patient experiences nodule formation. Early-onset lesions can be treated with subcision or injected with sterile water. Later-onset nodules can be treated with intralesional triamcinolone up to 40 mg/mL or 5-fluorouracil 2% or 5% combined with a low-dose oral tetracycline antibiotic. There are some reports that oral prednisone may be used to help suppress the formation of nodules. Inappropriate placement of this product in the skin can lead to lumpiness or visibility of the filler through the skin. Post-treatment massage to the area can help decrease this risk."}
{"id": "article-511_17", "title": "Poly-L-Lactic Acid -- Adverse Effects", "content": "Post-procedural infection is rare but can occur. The skin should be prepped with an antiseptic such as alcohol, followed by chlorhexidine or chloroxylenol. Some injectors inquire about a history of HSV and provide adequate\u00a0prevention of antivirals up to 2 days before and\u00a02 days after treatment if augmentation is performed on or around the lip.", "contents": "Poly-L-Lactic Acid -- Adverse Effects. Post-procedural infection is rare but can occur. The skin should be prepped with an antiseptic such as alcohol, followed by chlorhexidine or chloroxylenol. Some injectors inquire about a history of HSV and provide adequate\u00a0prevention of antivirals up to 2 days before and\u00a02 days after treatment if augmentation is performed on or around the lip."}
{"id": "article-511_18", "title": "Poly-L-Lactic Acid -- Adverse Effects", "content": "Edema has been documented in correlation with erythema, nociception, and a sensation of heat. The symptoms were predominantly transient and exhibited no substantial detriment to the individual's quality of daily life. Treatment with corticosteroids, antihistamines, and anti-inflammatory drugs may be required. The resolution typically occurs within 7\u00a0to 10 days. [19] Paraffinoma of lower eyelids as a complication of PLLA has been reported. [20]", "contents": "Poly-L-Lactic Acid -- Adverse Effects. Edema has been documented in correlation with erythema, nociception, and a sensation of heat. The symptoms were predominantly transient and exhibited no substantial detriment to the individual's quality of daily life. Treatment with corticosteroids, antihistamines, and anti-inflammatory drugs may be required. The resolution typically occurs within 7\u00a0to 10 days. [19] Paraffinoma of lower eyelids as a complication of PLLA has been reported. [20]"}
{"id": "article-511_19", "title": "Poly-L-Lactic Acid -- Adverse Effects", "content": "The most feared complication of an injectable product is skin necrosis due to the cannulation of the product into a vessel with subsequent embolization or compression of a vessel from excessive volume. [21] Healthcare professionals should thoroughly understand the anatomy of the treatment area and be aware of any potential danger zones. Injection of low volumes over multiple treatment sessions should be used whenever possible. Aspiration should be performed before injecting the product into the tissue. Methods to promote vasodilation should be employed in the event of vascular compromise. The area should be treated with a warm compress and topical nitroglycerin to promote vasodilation. Drug - Drug Interactions", "contents": "Poly-L-Lactic Acid -- Adverse Effects. The most feared complication of an injectable product is skin necrosis due to the cannulation of the product into a vessel with subsequent embolization or compression of a vessel from excessive volume. [21] Healthcare professionals should thoroughly understand the anatomy of the treatment area and be aware of any potential danger zones. Injection of low volumes over multiple treatment sessions should be used whenever possible. Aspiration should be performed before injecting the product into the tissue. Methods to promote vasodilation should be employed in the event of vascular compromise. The area should be treated with a warm compress and topical nitroglycerin to promote vasodilation. Drug - Drug Interactions"}
{"id": "article-511_20", "title": "Poly-L-Lactic Acid -- Adverse Effects", "content": "Injection site reaction increases if the patient takes a blood-thinning agent, such as aspirin, warfarin, clopidogrel, apixaban, rivaroxaban, and dabigatran. Clinicians should\u00a0carefully review the patient's medication list and counsel them regarding the increased risk. Patients with coagulation disorders or those receiving anticoagulant therapy are at increased risk of hematoma formation and bleeding at the injection site during poly-L-lactic\u00a0acid treatment.\u00a0Smoking impairs the healing outcome of guided tissue regeneration treatment of intra-bony defects. [22] No clinical studies have been performed to\u00a0analyze the interactions of PLLA with local anesthetics, co-administered drugs, or concurrent devices. Mixing poly-L-lactic\u00a0acid with other dermal filler products is not recommended.", "contents": "Poly-L-Lactic Acid -- Adverse Effects. Injection site reaction increases if the patient takes a blood-thinning agent, such as aspirin, warfarin, clopidogrel, apixaban, rivaroxaban, and dabigatran. Clinicians should\u00a0carefully review the patient's medication list and counsel them regarding the increased risk. Patients with coagulation disorders or those receiving anticoagulant therapy are at increased risk of hematoma formation and bleeding at the injection site during poly-L-lactic\u00a0acid treatment.\u00a0Smoking impairs the healing outcome of guided tissue regeneration treatment of intra-bony defects. [22] No clinical studies have been performed to\u00a0analyze the interactions of PLLA with local anesthetics, co-administered drugs, or concurrent devices. Mixing poly-L-lactic\u00a0acid with other dermal filler products is not recommended."}
{"id": "article-511_21", "title": "Poly-L-Lactic Acid -- Adverse Effects -- Imaging Interference", "content": "The radiopacity of poly-L-lactic\u00a0acid in humans remains uncertain; microparticles may be detectable on specific imaging modalities. [23]", "contents": "Poly-L-Lactic Acid -- Adverse Effects -- Imaging Interference. The radiopacity of poly-L-lactic\u00a0acid in humans remains uncertain; microparticles may be detectable on specific imaging modalities. [23]"}
{"id": "article-511_22", "title": "Poly-L-Lactic Acid -- Contraindications", "content": "A known allergy to poly-L-lactic acid or any components (carboxymethylcellulose\u00a0or non-pyrogenic mannitol)\u00a0represents an absolute contraindication to treatment. Poly-L-lactic acid (PLLA) is contraindicated for use in patients with a documented history of or a predisposition to keloid formation or hypertrophic scarring. [24]", "contents": "Poly-L-Lactic Acid -- Contraindications. A known allergy to poly-L-lactic acid or any components (carboxymethylcellulose\u00a0or non-pyrogenic mannitol)\u00a0represents an absolute contraindication to treatment. Poly-L-lactic acid (PLLA) is contraindicated for use in patients with a documented history of or a predisposition to keloid formation or hypertrophic scarring. [24]"}
{"id": "article-511_23", "title": "Poly-L-Lactic Acid -- Contraindications -- Box Warnings", "content": "PLLA filler injection must not be injected into blood vessels due to potential complications such as vessel occlusion, ischemia, or infarction.", "contents": "Poly-L-Lactic Acid -- Contraindications -- Box Warnings. PLLA filler injection must not be injected into blood vessels due to potential complications such as vessel occlusion, ischemia, or infarction."}
{"id": "article-511_24", "title": "Poly-L-Lactic Acid -- Contraindications -- Box Warnings", "content": "Rare and severe adverse events due to the IV injection of soft tissue fillers in the face have been reported, including temporary or permanent vision impairment, blindness, and cerebral ischemia. If a patient exhibits symptoms such as changes in vision, signs of a stroke, skin paleness, or unusual pain during or after the procedure, the injection should be immediately stopped. Evaluation by a specialist may be necessary. [18] PLLA filler injection in specific sites with active inflammatory processes or infections should be postponed until the inflammatory condition is resolved and controlled. Delayed inflammatory reactions to dermal fillers have been reported following vaccination with mRNA COVID-19 vaccines. [25] [26]", "contents": "Poly-L-Lactic Acid -- Contraindications -- Box Warnings. Rare and severe adverse events due to the IV injection of soft tissue fillers in the face have been reported, including temporary or permanent vision impairment, blindness, and cerebral ischemia. If a patient exhibits symptoms such as changes in vision, signs of a stroke, skin paleness, or unusual pain during or after the procedure, the injection should be immediately stopped. Evaluation by a specialist may be necessary. [18] PLLA filler injection in specific sites with active inflammatory processes or infections should be postponed until the inflammatory condition is resolved and controlled. Delayed inflammatory reactions to dermal fillers have been reported following vaccination with mRNA COVID-19 vaccines. [25] [26]"}
{"id": "article-511_25", "title": "Poly-L-Lactic Acid -- Contraindications -- Warnings and Precautions", "content": "The safety and effectiveness of poly-L-lactic\u00a0acid (PLLA) in various dosages, frequencies, injection sites, techniques, or in conjunction with\u00a0other dermal filler injections have not undergone evaluation. Using poly-L-lactic\u00a0acid (PLLA) in the lips\u00a0requires caution;\u00a0clinicians should not\u00a0inject it into the vermillion of the lip. Care should be exercised when administering poly-L-lactic acid (PLLA) to patients with thin skin. [17] Poly-L-lactic acid (PLLA) injections in the peri-orbital region can cause nodules and papules. [27] Used syringes and needles containing poly-L-lactic\u00a0acid (PLLA) are considered biohazardous and should be handled and disposed of by established medical practices and relevant regulations.", "contents": "Poly-L-Lactic Acid -- Contraindications -- Warnings and Precautions. The safety and effectiveness of poly-L-lactic\u00a0acid (PLLA) in various dosages, frequencies, injection sites, techniques, or in conjunction with\u00a0other dermal filler injections have not undergone evaluation. Using poly-L-lactic\u00a0acid (PLLA) in the lips\u00a0requires caution;\u00a0clinicians should not\u00a0inject it into the vermillion of the lip. Care should be exercised when administering poly-L-lactic acid (PLLA) to patients with thin skin. [17] Poly-L-lactic acid (PLLA) injections in the peri-orbital region can cause nodules and papules. [27] Used syringes and needles containing poly-L-lactic\u00a0acid (PLLA) are considered biohazardous and should be handled and disposed of by established medical practices and relevant regulations."}
{"id": "article-511_26", "title": "Poly-L-Lactic Acid -- Contraindications -- Warnings and Precautions", "content": "If laser treatment or other procedures inducing an active dermal response are contemplated following poly-L-lactic\u00a0acid (PLLA) treatment, there is a potential risk of an inflammatory reaction at the implant site, particularly if the skin has not completely healed. [28]", "contents": "Poly-L-Lactic Acid -- Contraindications -- Warnings and Precautions. If laser treatment or other procedures inducing an active dermal response are contemplated following poly-L-lactic\u00a0acid (PLLA) treatment, there is a potential risk of an inflammatory reaction at the implant site, particularly if the skin has not completely healed. [28]"}
{"id": "article-511_27", "title": "Poly-L-Lactic Acid -- Monitoring", "content": "All patients should be assessed before treatment for facial asymmetry and volume differences. Documentation of any preexisting scars and inquire about a history of keloid formation is essential. All patients should receive baseline photographs and return for assessment 2 to 4 weeks after injection. Patients should be advised to avoid unnecessary herbal medications and supplements to decrease the risk of bruising. Anticoagulants should not be discontinued.", "contents": "Poly-L-Lactic Acid -- Monitoring. All patients should be assessed before treatment for facial asymmetry and volume differences. Documentation of any preexisting scars and inquire about a history of keloid formation is essential. All patients should receive baseline photographs and return for assessment 2 to 4 weeks after injection. Patients should be advised to avoid unnecessary herbal medications and supplements to decrease the risk of bruising. Anticoagulants should not be discontinued."}
{"id": "article-511_28", "title": "Poly-L-Lactic Acid -- Monitoring", "content": "The FDA\u00a0has warned\u00a0against using non-approved needle-free devices for injecting dermal fillers. Only FDA-approved fillers should be prescribed, using a syringe and needle or cannula. Healthcare providers should caution patients against purchasing needle-free devices online. Adverse effects from these devices should be reported to the FDA's MedWatch system. [29]", "contents": "Poly-L-Lactic Acid -- Monitoring. The FDA\u00a0has warned\u00a0against using non-approved needle-free devices for injecting dermal fillers. Only FDA-approved fillers should be prescribed, using a syringe and needle or cannula. Healthcare providers should caution patients against purchasing needle-free devices online. Adverse effects from these devices should be reported to the FDA's MedWatch system. [29]"}
{"id": "article-511_29", "title": "Poly-L-Lactic Acid -- Toxicity", "content": "There is no antidote to dissolve poly-L-lactic acid. In a vascular compromise, methods to promote vasodilation should be employed. To promote vasodilation, the area should be treated with warm compresses and topical nitroglycerin.", "contents": "Poly-L-Lactic Acid -- Toxicity. There is no antidote to dissolve poly-L-lactic acid. In a vascular compromise, methods to promote vasodilation should be employed. To promote vasodilation, the area should be treated with warm compresses and topical nitroglycerin."}
{"id": "article-511_30", "title": "Poly-L-Lactic Acid -- Enhancing Healthcare Team Outcomes", "content": "Poly-L-lactic acid is an absorbable, semi-permanent, injectable implant that can gradually restore volume and stimulate collagen formation.\u00a0The drug is FDA-approved for correcting facial fat loss associated with antiretroviral therapy-induced lipoatrophy in HIV patients.", "contents": "Poly-L-Lactic Acid -- Enhancing Healthcare Team Outcomes. Poly-L-lactic acid is an absorbable, semi-permanent, injectable implant that can gradually restore volume and stimulate collagen formation.\u00a0The drug is FDA-approved for correcting facial fat loss associated with antiretroviral therapy-induced lipoatrophy in HIV patients."}
{"id": "article-511_31", "title": "Poly-L-Lactic Acid -- Enhancing Healthcare Team Outcomes", "content": "Poly-L-lactic acid (PLLA) should be administered exclusively by trained healthcare professionals with comprehensive training. While this dermal filler is usually only injected by dermatologists and plastic surgeons, primary care providers and advanced practice practitioners should know which patients may benefit from it.", "contents": "Poly-L-Lactic Acid -- Enhancing Healthcare Team Outcomes. Poly-L-lactic acid (PLLA) should be administered exclusively by trained healthcare professionals with comprehensive training. While this dermal filler is usually only injected by dermatologists and plastic surgeons, primary care providers and advanced practice practitioners should know which patients may benefit from it."}
{"id": "article-511_32", "title": "Poly-L-Lactic Acid -- Enhancing Healthcare Team Outcomes", "content": "Before treatment, healthcare practitioners should thoroughly discuss potential risks and complications with patients. In addition, the healthcare team should advise patients to minimize sun exposure and avoid ultraviolet light exposure in the treated area.", "contents": "Poly-L-Lactic Acid -- Enhancing Healthcare Team Outcomes. Before treatment, healthcare practitioners should thoroughly discuss potential risks and complications with patients. In addition, the healthcare team should advise patients to minimize sun exposure and avoid ultraviolet light exposure in the treated area."}
{"id": "article-511_33", "title": "Poly-L-Lactic Acid -- Enhancing Healthcare Team Outcomes", "content": "Nurses and pharmacists should monitor the patients for adverse effects. Patients\u00a0require education regarding the drug's adverse effects, potential complications, and durability. Open communication between\u00a0all interprofessional team members and patients can lead to\u00a0optimal benefits from poly-L-lactic acid when indicated.", "contents": "Poly-L-Lactic Acid -- Enhancing Healthcare Team Outcomes. Nurses and pharmacists should monitor the patients for adverse effects. Patients\u00a0require education regarding the drug's adverse effects, potential complications, and durability. Open communication between\u00a0all interprofessional team members and patients can lead to\u00a0optimal benefits from poly-L-lactic acid when indicated."}
{"id": "article-511_34", "title": "Poly-L-Lactic Acid -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Poly-L-Lactic Acid -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}